Skip to content
Screener

Aardvark Therapeutics, Inc. AARD Q1 2025 Annual earnings

Reported May 14, 2025 · Before market open

Revenue-
EPS-$0.71Miss by $0.04
EPS estimate-$0.67

Next report

Nov 12, 2026 (in a month)
EPS estimate-$0.74

Financials

Q1 2025

Income statement

See full
Revenue-—
Operating income-$10.5M-382%
Net income-$9.3M-327%
EPS (diluted)-$0.71-29.1%

Balance sheet

See full
Cash & equivalents$26.5M—
Total debt$726.0K—
Total equity$150.7M+508%
Total assets$157.0M—

Cash flow

See full
Operating cash flow-$11.4M-420%
CapEx--100%
Free cash flow-$11.4M-419%

FAQ

When did Aardvark Therapeutics, Inc. report Q1 2025 earnings?
Aardvark Therapeutics, Inc. (AARD) reported Q1 2025 earnings on May 14, 2025 before market open.
What were Aardvark Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Aardvark Therapeutics, Inc. reported revenue of - and eps of $-0.71 for Q1 2025.
Did Aardvark Therapeutics, Inc. beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.67 by $0.04.
Where can I find Aardvark Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-071477) and the 10-K periodic report (0000950170-25-047835) directly on SEC EDGAR. The filing index links above go to sec.gov.